
Solana Company (NASDAQ:HSDT – Free Report) – Maxim Group issued their Q3 2026 EPS estimates for Solana in a research report issued to clients and investors on Tuesday, November 10th. Maxim Group analyst M. Galinko anticipates that the company will earn ($0.04) per share for the quarter. The consensus estimate for Solana’s current full-year earnings is ($0.25) per share.
Solana (NASDAQ:HSDT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 11th. The company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $1.18. Solana had a net margin of 2,040.43% and a return on equity of 134.60%. The company had revenue of $3.36 million during the quarter, compared to the consensus estimate of $2.85 million.
Get Our Latest Stock Report on Solana
Solana Price Performance
NASDAQ HSDT opened at $1.73 on Thursday. Solana has a 1-year low of $1.19 and a 1-year high of $4.93. The company has a market capitalization of $105.08 million, a P/E ratio of 0.46 and a beta of 1.10. The business has a 50 day moving average price of $2.35 and a 200 day moving average price of $2.05.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Solana stock. Saba Capital Management L.P. acquired a new position in shares of Solana Company (NASDAQ:HSDT – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 65,210 shares of the company’s stock, valued at approximately $113,000. Saba Capital Management L.P. owned 0.12% of Solana at the end of the most recent reporting period. Institutional investors and hedge funds own 18.63% of the company’s stock.
About Solana
Solana Company (NASDAQ: HSDT) is a publicly traded company focused on a digital-asset treasury strategy centered on SOL, the native token of the Solana blockchain. It is a corporate holder of Solana-related digital assets, rather than the operator of the Solana network. The company was formerly Helius Medical Technologies, a medical technology business that developed the Portable Neuromodulation Stimulator (PoNS), a device designed to support rehabilitation for people with certain neurological conditions.
Recommended Stories
- Five stocks we like better than Solana
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Solana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solana and related companies with MarketBeat.com's FREE daily email newsletter.
